---
title: "First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295708147.md"
description: "In San Diego on August 12, 2026, First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a biotech company focusing on antibody therapeutics for autoimmune and inflammatory diseases, announced their financial results for the second quarter of 2026 ending on June 30. The company also shared a general business update."
datetime: "2026-08-12T20:29:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295708147.md)
  - [en](https://longbridge.com/en/news/295708147.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295708147.md)
generator: "portal-rs"
---

# First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

In San Diego on August 12, 2026, First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a biotech company focusing on antibody therapeutics for autoimmune and inflammatory diseases, announced their financial results for the second quarter of 2026 ending on June 30. The company also shared a general business update.

### Related Stocks

- [TRAX.US](https://longbridge.com/en/quote/TRAX.US.md)

## Related News & Research

- [McKenzie Scott PC Announces Three San Diego Civil Rights Case Outcomes](https://longbridge.com/en/news/296538482.md)
- [Tiziana Life Sciences launches Phase 2a BANYAN trial of intranasal foralumab in ALS](https://longbridge.com/en/news/296776352.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)
- [10:31 ETLiver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight](https://longbridge.com/en/news/296802956.md)
- [Turn Therapeutics says mouse study shows GX-03 cuts dermatitis severity 66%](https://longbridge.com/en/news/296487429.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**